Hepcidin agonists including BMP6; VIT-2763, which is a ferroportin blocker; antisense oligonucleotides; and siRNAs that inactivate matriptase-2 to increase endogenous hepcidin production are promising therapeutic agents that reduce iron overload [88]. This evidence concerns the gene HAMP and Tangier disease.